A structured summary of a study protocol for a randomised controlled trial of Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E) has been published in the BioMed Central Journal.
The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with strongly suspected or confirmed COVID-19. By targeting the exaggerated host response mechanisms driving the severe lung and other organ damage seen in coronavirus infection, this approach is a way of finding out whether these novel approaches are effective in treating the disease.
The treatments currently being tested in TACTIC-E are:
The platform design used by TACTIC-E provides flexibility to swap out and add in alternative treatments based on emerging data as the trial progresses.
For more information visit: CamCovidTrials
Published July 31, 2020
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.